Eaton Vance Management Has $38.34 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Eaton Vance Management decreased its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 7.8% during the 4th quarter, HoldingsChannel reports. The firm owned 270,785 shares of the company’s stock after selling 22,830 shares during the quarter. Eaton Vance Management’s holdings in 10x Genomics were worth $38,343,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of TXG. BlackRock Inc. increased its stake in shares of 10x Genomics by 57.0% in the 4th quarter. BlackRock Inc. now owns 5,163,020 shares of the company’s stock valued at $731,084,000 after purchasing an additional 1,874,510 shares during the last quarter. FMR LLC increased its stake in shares of 10x Genomics by 17.3% in the 4th quarter. FMR LLC now owns 10,071,083 shares of the company’s stock valued at $1,426,065,000 after purchasing an additional 1,484,389 shares during the last quarter. William Blair Investment Management LLC bought a new position in shares of 10x Genomics in the 4th quarter valued at $181,568,000. Nuveen Asset Management LLC increased its stake in shares of 10x Genomics by 212.8% in the 3rd quarter. Nuveen Asset Management LLC now owns 1,001,406 shares of the company’s stock valued at $124,856,000 after purchasing an additional 681,250 shares during the last quarter. Finally, Brown Capital Management LLC bought a new position in shares of 10x Genomics in the 4th quarter valued at $64,887,000. Institutional investors own 68.84% of the company’s stock.

TXG has been the topic of several recent analyst reports. Zacks Investment Research upgraded 10x Genomics from a “sell” rating to a “hold” rating in a research note on Thursday, March 25th. Morgan Stanley lifted their price target on 10x Genomics from $145.00 to $215.00 and gave the company an “overweight” rating in a research note on Thursday, February 25th. Cowen boosted their price objective on 10x Genomics from $155.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, February 25th. Smith Barney Citigroup boosted their price objective on 10x Genomics from $165.00 to $195.00 in a research report on Wednesday, December 16th. Finally, William Blair initiated coverage on 10x Genomics in a research report on Monday, March 22nd. They set an “outperform” rating on the stock. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $183.70.

NASDAQ TXG opened at $185.34 on Thursday. The business’s 50-day moving average price is $174.12 and its two-hundred day moving average price is $158.90. 10x Genomics, Inc. has a 12 month low of $59.36 and a 12 month high of $201.70. The firm has a market capitalization of $20.16 billion, a PE ratio of -137.29 and a beta of 1.39.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Tuesday, February 16th. The company reported ($3.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($3.59). 10x Genomics had a negative net margin of 51.27% and a negative return on equity of 19.98%. The company had revenue of $112.22 million during the quarter, compared to the consensus estimate of $101.20 million. On average, analysts forecast that 10x Genomics, Inc. will post -1.18 earnings per share for the current year.

In other 10x Genomics news, Director Sridhar Kosaraju sold 1,500 shares of the company’s stock in a transaction dated Tuesday, March 23rd. The stock was sold at an average price of $174.63, for a total value of $261,945.00. Following the sale, the director now owns 2,833 shares in the company, valued at approximately $494,726.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Benjamin J. Hindson sold 41,666 shares of the company’s stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $184.54, for a total value of $7,689,043.64. Following the completion of the sale, the insider now owns 78,302 shares in the company, valued at approximately $14,449,851.08. The disclosure for this sale can be found here. Insiders sold a total of 144,416 shares of company stock worth $25,731,264 in the last quarter. Corporate insiders own 13.28% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products.

Further Reading: Determine Your Level of Risk Tolerance

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.